LY83583 exhibits a broad spectrum of inhibitory and regulatory activities across different biological systems. In the context of vascular biology, it shows inhibitory activity in the vasorelaxation process induced by acetylcholine on phenylephrine-precontracted rat aorta with intact endothelium, featuring an EC50 value of 335.0 nM and achieving 77.0% of maximal acetylcholine-induced vasorelaxation. In yeast assays, LY83583 inhibits the cytostatic effect of 50 nM rapamycin in Saccharomyces cerevisiae strain BY4742 with an EC50 value of 10400.0 nM and affects the expression of a variety of genes, indicating its regulatory roles in gene expression. Specifically, it increases the expressions of GUF1, FMP38, HMI1, YRR1, YDR514C, SUV3, PET111, MDL1, MRPS28, and MAM1, while decreasing the expressions of FET4, RIM11, HOS1, YDR222W, YKR75C, YJL051W, SGN1, and YMD8. Additionally, LY83583 inhibits yeast Guf1 with an IC50 value of 300000.0 nM. It also exhibits potency in a range of assays, including inhibition of Tyrosyl-DNA Phosphodiesterase (TDP1), Tau Fibril Formation, ROR gamma transcriptional activity, Aldehyde Dehydrogenase, Bacillus subtilis Sfp phosphopantetheinyl transferase, IMPase, Histone Lysine Methyltransferase G9a, and the Menin-MLL Interaction. Furthermore, it shows activity against Glioma stress response, vitamin D receptor inhibition, and viral binding or entry inhibition for Lassa Virus, Marburg Virus, and Foot and Mouth Disease Virus. Notably, LY83583 also inhibits soluble guanylate cyclase with an IC50 value of 1000.0 nM. These diverse activities suggest that LY83583 has potential therapeutic implications across various biological pathways and disease models..
Note: Summary generated by AI. Data source: ChEMBL 